Company News in the Life Science Industry

»

Reset 

Orphazyme A/S provides update on previously announced global offering

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Orphazyme A/S

Opthea Files Registration Statement for Proposed Initial Public Offering in the United States

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Opthea Limited

Aesthetic Medical International Holdings Group Limited Reports Second Quarter 2020 Unaudited Financial Results

Read more ››
By: GlobenewsWire - 25 Sep 2020

CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting

SUZHOU, China, Sept. 25, 2020 /PRNewswire/ -- CStone Pharmaceuticals (SUZHOU) Co., Ltd. ("CStone", HKEX: 2616) presented positive results at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting from a phase I/II bridging study in China evaluating avapritinib in patients with unresectable... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  CStone Pharmaceuticals

RDIF and LAXISAM agree to supply up to 35 million doses of Sputnik V vaccine to Uzbekistan

MOSCOW, Sept. 25, 2020 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and LAXISAM, one of the leading pharmaceutical companies in the Republic of Uzbekistan, have agreed to supply to the country up to 35 million doses of the Sputnik V vaccine, which... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020

CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting

SUZHOU, China, Sept. 25, 2020 /PRNewswire/ -- CStone Pharmaceuticals (Suzhou) Co., Ltd. ("CStone", HKSE: 2616) announced the updated results from two studies of its anti-PD-L1 monoclonal antibody sugemalimab (CS1001) at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. These... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  CStone Pharmaceuticals

Nordic Nanovector ASA - Tranche 2 share capital increase registered

OSLO, Norway, Sept. 25, 2020 /PRNewswire/ -- Reference is made to the stock exchange announcement on 25 September 2020 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  Nanobiotix SA | Nanoco Technologies Ltd.   | Nordic Nanovector ASA

Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

GOTHENBURG, Sweden, Sept. 25, 2020 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces effects of VP01 on idiopathic pulmonary fibrosis (IPF) patient tissue.

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2020

Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis

- Focus on effect of SVec(™) on downregulation of pathological immune responses underlying the destruction of own cells in DM1 and in MS patients

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2020

Radius Health & Menarini Group Provide Elacestrant Update

WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /CNW/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  Radius Health, Inc.

CureDuchenne Congratulates Dyne Therapeutics On Its Initial Public Offering

NEWPORT BEACH, Calif., Sept. 25, 2020 /PRNewswire/ -- CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy, is celebrating Dyne Therapeutics' successful initial public offering and subsequent listing on NASDAQ.

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  CureDuchenne | CureDuchenne Ventures, LLC

Graybug Vision Announces Pricing of Upsized Initial Public Offering

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Graybug Vision, Inc.

Prelude Therapeutics Announces Pricing of Initial Public Offering

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Prelude Pharmaceutical Co., Ltd. | Prelude Therapeutics Incorporated | Prelude Fertility, Inc. | Prelude Ventures LLC

OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  OliX Pharmaceuticals, Inc

Nyxoah announces the end of the Stabilisation Period and the Full Exercise of the Over-allotment Option

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Nyxoah S.A

APACMed hosts first ever hybrid conference

SINGAPORE, Sept. 25, 2020 /PRNewswire/ -- The Asia Pacific Medical Technology Association (APACMed) brought to fruition the first-ever hybrid virtual forum - Redefining Healthcare Agility, on 24(th) September 2020, which welcomed more than 130 world class leaders from over 30 countries... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020

Pangyo Techno Valley's 100 Bio & Medical Special - MIK HOT SPOT Online Exhibition to open on September 4

SEOUL, South Korea, Sept. 25, 2020 /PRNewswire/ -- AVING NEWS' Korea's only convention media and online exhibition center by itself, began this project to help Korean companies to enter the domestic and foreign markets through MIK HOT SPOT (Made in Korea Online Exhibition) on its way to become... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  Avinger, Inc.

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA

NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary... Read more ››

By: PR Newswire Association LLC. - 25 Sep 2020

Advisory - All strengths of MAR-Diltiazem CD, a drug used to treat angina and hypertension, have been recalled because of dosing concerns

OTTAWA, ON, Sept. 24, 2020 /CNW/ -

Read more ››
By: PR Newswire Association LLC. - 25 Sep 2020
Related companies:  Health Canada Atlantic Regional Office

Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform

Read more ››
By: GlobenewsWire - 25 Sep 2020
Related companies:  Rockwell Medical, Inc.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19 20  21  22  23  24  25 »

Explore our database of over 50,000 companies